KTTAW
Pasithea Therapeutics Corp. [KTTAW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
KTTAW Stock Summary
In the News
KTTAW Financial details
Company Rating
Neutral
Market Cap
8.55M
Income
-287.56M
Revenue
0
Book val./share
22.46
Cash/share
15.68
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-609.67
Forward P/E
-
PEG
-2.98
P/S
30.04
P/B
6154.22
P/C
0
P/FCF
-0.46
Quick Ratio
9.63
Current Ratio
10.16
Debt / Equity
0
LT Debt / Equity
-
-
-
EPS (TTM)
-221.65
EPS next Y
-
EPS next Q
-
EPS this Y
25.82%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
68.99%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
6.55%
Inst Trans
1.05%
ROA
-934%
ROE
-787%
ROC
-0.56%
Gross Margin
101%
Oper. Margin
-6610%
Profit Margin
-118986%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.015-0.015
52W High
-
52W Low
-
RSI
53
Rel Volume
-
Avg Volume
-
Volume
8.19K
Perf Week
13.82%
Perf Month
15.7%
Perf Quarter
-
Perf Half Y
17.65%
-
-
-
-
Beta
0.884
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.014
Change
12%
KTTAW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.01 | 0.39 | 0 | |
| Net income per share | -0.06 | -1.89 | -10.34 | -13.01 | |
| Operating cash flow per share | -0.06 | -2.76 | -11.54 | -10.95 | |
| Free cash flow per share | -0.06 | -2.78 | -13.23 | -10.97 | |
| Cash per share | 0.35 | 46.04 | 26.26 | 13.31 | |
| Book value per share | 0.35 | 44.7 | 33.67 | 19.08 | |
| Tangible book value per share | 0.35 | 44.7 | 25.86 | 11.57 | |
| Share holders equity per share | 0.35 | 44.7 | 33.67 | 19.08 | |
| Interest debt per share | 0 | 0 | 0.73 | 0.07 | |
| Market cap | 49.05M | 40.72M | 16.21M | 9.08M | |
| Enterprise value | 48.81M | -12.24M | -16.01M | -7.17M | |
| P/E ratio | -1.2K | -18.73 | -1.24 | -0.57 | |
| Price to sales ratio | 0 | 2.7K | 33.31 | 0 | |
| POCF ratio | -1.27K | -12.83 | -1.11 | -0.68 | |
| PFCF ratio | -1.27K | -12.74 | -0.97 | -0.67 | |
| P/B Ratio | 203.23 | 0.79 | 0.38 | 0.39 | |
| PTB ratio | 203.23 | 0.79 | 0.38 | 0.39 | |
| EV to sales | 0 | -812.77 | -32.91 | 0 | |
| Enterprise value over EBITDA | -1.19K | 2.72 | 1.09 | 0.47 | |
| EV to operating cash flow | -1.26K | 3.86 | 1.1 | 0.53 | |
| EV to free cash flow | -1.26K | 3.83 | 0.96 | 0.53 | |
| Earnings yield | 0 | -0.05 | -0.81 | -1.76 | |
| Free cash flow yield | 0 | -0.08 | -1.03 | -1.48 | |
| Debt to equity | 0 | 0 | 0.02 | 0 | |
| Debt to assets | 0 | 0 | 0.02 | 0 | |
| Net debt to EBITDA | 5.95 | 11.75 | 2.19 | 1.06 | |
| Current ratio | 37.55 | 119.17 | 18.15 | 6.34 | |
| Interest coverage | 0 | -8.87K | -145.26K | 0 | |
| Income quality | 0.94 | 1.46 | 1.04 | 0.87 | |
| Dividend Yield | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 20.4 | 0 | |
| Research and developement to revenue | 0 | 0 | 5.48 | 0 | |
| Intangibles to total assets | 0 | 0 | 0.22 | 0.35 | |
| Capex to operating cash flow | 0 | 0.01 | 0.15 | 0 | |
| Capex to revenue | 0 | -1.43 | -4.4 | 0 | |
| Capex to depreciation | 0 | -15.59 | -66.06 | -0.05 | |
| Stock based compensation to revenue | 0 | 31.29 | 1.14 | 0 | |
| Graham number | 0.68 | 43.59 | 88.51 | 74.73 | |
| ROIC | 0.08 | -0.09 | -0.31 | -20.53 | |
| Return on tangible assets | -0.17 | -0.04 | -0.37 | -0.94 | |
| Graham Net | 0.34 | 44.39 | 24.31 | 11.11 | |
| Working capital | 241.36K | 52.85M | 32.2M | 14.06M | |
| Tangible asset value | 241.36K | 51.42M | 32.65M | 14.19M | |
| Net current asset value | 241.36K | 51.4M | 31.39M | 13.97M | |
| Invested capital | 0 | 0 | 0.02 | 0 | |
| Average receivables | 0 | 0 | 151.07K | 171.32K | |
| Average payables | 0 | 226.94K | 1.03M | 807.17K | |
| Average inventory | 0 | 0 | 0.5 | -20.25K | |
| Days sales outstanding | 0 | 0 | 226.65 | 0 | |
| Days payables outstanding | 0 | 9.45K | 5.21K | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | -22.8 | |
| Receivables turnover | 0 | 0 | 1.61 | 0 | |
| Payables turnover | 0 | 0.04 | 0.07 | 0 | |
| Inventory turnover | 0 | 0 | 113.2K | -16.01 | |
| ROE | -0.17 | -0.04 | -0.31 | -0.68 | |
| Capex per share | 0 | -0.02 | -1.69 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.18 | 0 | 0 | 0 | 0 | |
| Net income per share | -3 | -211.05 | -2.88 | -2.87 | -4.85 | |
| Operating cash flow per share | -3.39 | -2.46 | -2.66 | -2.11 | -3.18 | |
| Free cash flow per share | -4.77 | -2.5 | -2.67 | -2.09 | -3.18 | |
| Cash per share | 25.46 | 22.95 | 20.4 | 15.57 | 15.68 | |
| Book value per share | 32.64 | 30.02 | 27.24 | 22.55 | 22.46 | |
| Tangible book value per share | 25.07 | 22.6 | 19.96 | 15.11 | 13.63 | |
| Share holders equity per share | 32.64 | 30.02 | 27.24 | 22.55 | 22.46 | |
| Interest debt per share | 0.71 | 0.56 | 0.43 | 0.31 | 0.08 | |
| Market cap | 16.72M | 9.78M | 12.8M | 12.08M | 7.71M | |
| Enterprise value | -15.5M | -19.41M | -13.29M | -7.12M | -8.54M | |
| P/E ratio | -1.07 | -0.01 | -0.85 | -0.84 | -0.38 | |
| Price to sales ratio | 69.46 | 0 | 0 | 0 | 0 | |
| POCF ratio | -3.78 | -3.05 | -3.68 | -4.55 | -2.33 | |
| PFCF ratio | -2.69 | -3 | -3.68 | -4.59 | -2.33 | |
| P/B Ratio | 0.39 | 0.25 | 0.36 | 0.43 | 0.33 | |
| PTB ratio | 0.39 | 0.25 | 0.36 | 0.43 | 0.33 | |
| EV to sales | -64.39 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 3.72 | 6.36 | 3.51 | 1.88 | 1.71 | |
| EV to operating cash flow | 3.51 | 6.06 | 3.82 | 2.68 | 2.58 | |
| EV to free cash flow | 2.5 | 5.96 | 3.82 | 2.71 | 2.58 | |
| Earnings yield | -0.23 | -28.14 | -0.29 | -0.3 | -0.65 | |
| Free cash flow yield | -0.37 | -0.33 | -0.27 | -0.22 | -0.43 | |
| Debt to equity | 0.02 | 0.02 | 0.02 | 0.01 | 0 | |
| Debt to assets | 0.02 | 0.02 | 0.01 | 0.01 | 0 | |
| Net debt to EBITDA | 7.74 | 9.57 | 6.9 | 5.07 | 3.26 | |
| Current ratio | 18.15 | 14.66 | 12.58 | 10.16 | 6.34 | |
| Interest coverage | -49.81K | -502.9 | 0 | 0 | 0 | |
| Income quality | 0.86 | 0.98 | 0.97 | 0.73 | 0.66 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 5.76 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.22 | 0.23 | 0.25 | 0.31 | 0.35 | |
| Capex to operating cash flow | 0.4 | 0.02 | 0 | -0.01 | 0 | |
| Capex to revenue | -7.43 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 18.44K | -0.33 | -0.02 | 0.14 | 0 | |
| Stock based compensation to revenue | 0.65 | 0 | 0 | 0 | 0 | |
| Graham number | 46.91 | 377.56 | 42.02 | 38.17 | 49.49 | |
| ROIC | -0.09 | -6.71 | -0.1 | -0.12 | -0.22 | |
| Return on tangible assets | -0.11 | -8.5 | -0.13 | -0.17 | -0.3 | |
| Graham Net | 23.57 | 21.08 | 18.82 | 14.2 | 13.08 | |
| Working capital | 32.2M | 28.99M | 25.81M | 18.73M | 14.06M | |
| Tangible asset value | 32.65M | 29.46M | 26.07M | 19.01M | 14.19M | |
| Net current asset value | 31.39M | 28.2M | 25.48M | 18.49M | 13.97M | |
| Invested capital | 0.02 | 0.02 | 0.02 | 0.01 | 0 | |
| Average receivables | 151.07K | 158.96K | 69.14K | 108.75K | 67.75K | |
| Average payables | 1.44M | 1.53M | 1.69M | 963.02K | 0 | |
| Average inventory | 0.5 | 460.24K | 867.53K | 899.82K | 472.28K | |
| Days sales outstanding | 112.96 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 111.08K | 800.83 | 1.06K | 0 | 0 | |
| Days of inventory on hand | 0.07 | 509.24 | 449.17 | 546.4 | -22.47 | |
| Receivables turnover | 0.8 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0.11 | 0.08 | 0 | 0 | |
| Inventory turnover | 1.31K | 0.18 | 0.2 | 0.16 | -4.01 | |
| ROE | -0.09 | -7.03 | -0.11 | -0.13 | -0.22 | |
| Capex per share | -1.37 | -0.04 | 0 | 0.02 | 0 |
KTTAW Frequently Asked Questions
What is Pasithea Therapeutics Corp. stock symbol ?
Pasithea Therapeutics Corp. is a US stock , located in Miami beach of Fl and trading under the symbol KTTAW
What is Pasithea Therapeutics Corp. stock quote today ?
Pasithea Therapeutics Corp. stock price is $0.014 today.
Is Pasithea Therapeutics Corp. stock public?
Yes, Pasithea Therapeutics Corp. is a publicly traded company.
Company Profile
- Market Capitalization 8.55M
- Employee 8
- CEO Dr. Tiago Reis Marques M.D., Ph.D.
- Headquarters Miami Beach,FL,US
- IPO Date 2021-09-15
-
Website
http://pasitheaclinics.com 
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. The company also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. Pasithea Therapeutics Corp. was incorporated in 2020 and is based in Miami Beach, Florida.
